dc.contributor.author |
Khalil, Samar |
dc.contributor.author |
Bardawil, Tara |
dc.contributor.author |
Saade, Serena |
dc.contributor.author |
Chedraoui, Adele |
dc.contributor.author |
Ramadan, Nehmat |
dc.contributor.author |
Hasbani, Divina Justina |
dc.contributor.author |
Abbas, Ossama M. |
dc.contributor.author |
Nemer, Georges M. |
dc.contributor.author |
Rubeiz, Nelly George |
dc.contributor.author |
Kurban, Mazen S. |
dc.date.accessioned |
2025-01-24T11:40:46Z |
dc.date.available |
2025-01-24T11:40:46Z |
dc.date.issued |
2018 |
dc.identifier.uri |
http://hdl.handle.net/10938/29565 |
dc.description.abstract |
IMPORTANCE Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of disorders caused by defects in signaling pathways involved in epidermal proliferation and differentiation, leading to a wide range of skin manifestations. Therapeutic options are limited and often unsatisfactory. Topical cholesterol and statin as a combined formulation has proven successful in the treatment of patients with CHILD syndrome (congenital hemidysplasia ichthyosis and limb defects). OBJECTIVE To assess change in disease severity score after a 3-month therapeutic regimen consisting of a glycolic acid, 10% to 20%, cream and a combination cream of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. DESIGN, SETTING, AND PARTICIPANTS This case series of 15 patients with ARCI was conducted at the American University of Beirut, a referral center in the Middle East region for genodermatoses, between May 2017 and January 2018. No age groups were excluded; all patients were from the Middle East area; and all were initially not responsive to treatment with hydrating creams in combination with urea creams, 30% to 40%, or glycolic acid, 10% to 20%. Excluded were patients who had been taking systemic retinoids within 3 months before the start of the study. INTERVENTIONS A 3-month therapeutic regimen of glycolic acid, 10% to 20%, cream and a combination of lovastatin, 2%, with cholesterol, 2%, cream. MAIN OUTCOMES AND MEASURES Percentage change in disease severity scores following 2 and 3 months of study treatment. RESULTS Of the 15 patients included in the study, 10 were male (mean age, 11.2 years; age range, 2-38 years). The average percentage reduction in the disease severity score was 33.7% at 2 months (from 60.8 to 40.2) and 57.5% at 3 months (from 60.8 to 21.9). Adverse effects were mild and consisted mainly of irritation and burning. CONCLUSIONS AND RELEVANCE These findings suggest a benefit from a treatment regimen consisting of glycolic acid, 10% to 20%, and a combination of lovastatin, 2%, with cholesterol, 2%, in the treatment of ARCI. This combination of creams might also prove to be beneficial in other types of ichthyoses and other dermatological diseases with a defective skin barrier. © 2018 American Medical Association. All rights reserved. |
dc.language.iso |
en |
dc.publisher |
American Medical Association |
dc.relation.ispartof |
JAMA Dermatology |
dc.source |
Scopus |
dc.subject |
Administration, topical |
dc.subject |
Adolescent |
dc.subject |
Adult |
dc.subject |
Biopsy |
dc.subject |
Child |
dc.subject |
Child, preschool |
dc.subject |
Cholesterol |
dc.subject |
Drug combinations |
dc.subject |
Drug therapy, combination |
dc.subject |
Female |
dc.subject |
Follow-up studies |
dc.subject |
Glycolates |
dc.subject |
Humans |
dc.subject |
Hydroxymethylglutaryl-coa reductase inhibitors |
dc.subject |
Ichthyosis, lamellar |
dc.subject |
Keratolytic agents |
dc.subject |
Lovastatin |
dc.subject |
Male |
dc.subject |
Ointments |
dc.subject |
Prognosis |
dc.subject |
Retrospective studies |
dc.subject |
Severity of illness index |
dc.subject |
Skin |
dc.subject |
Young adult |
dc.subject |
Glycolic acid |
dc.subject |
Mevinolin |
dc.subject |
Glycolic acid derivative |
dc.subject |
Hydroxymethylglutaryl coenzyme a reductase inhibitor |
dc.subject |
Keratolytic agent |
dc.subject |
Article |
dc.subject |
Autosomal recessive congenital ichthyosis |
dc.subject |
Autosomal recessive disorder |
dc.subject |
Clinical article |
dc.subject |
Disease assessment |
dc.subject |
Disease classification |
dc.subject |
Disease severity |
dc.subject |
Drug use |
dc.subject |
Genodermatosis |
dc.subject |
Groups by age |
dc.subject |
Human |
dc.subject |
Ichthyosis |
dc.subject |
Middle east |
dc.subject |
Priority journal |
dc.subject |
School child |
dc.subject |
Scoring system |
dc.subject |
Skin burning sensation |
dc.subject |
Skin irritation |
dc.subject |
Treatment duration |
dc.subject |
Treatment outcome |
dc.subject |
Treatment response |
dc.subject |
Combination drug therapy |
dc.subject |
Drug combination |
dc.subject |
Follow up |
dc.subject |
Lamellar ichthyosis |
dc.subject |
Ointment |
dc.subject |
Pathology |
dc.subject |
Preschool child |
dc.subject |
Retrospective study |
dc.subject |
Topical drug administration |
dc.title |
Use of topical glycolic acid plus a lovastatin-cholesterol combination cream for the treatment of autosomal recessive congenital ichthyoses |
dc.type |
Article |
dc.contributor.department |
Dermatology |
dc.contributor.department |
Biochemistry and Molecular Genetics |
dc.contributor.faculty |
Faculty of Medicine (FM) |
dc.contributor.institution |
American University of Beirut |
dc.identifier.doi |
https://doi.org/10.1001/jamadermatol.2018.2904 |
dc.identifier.pmid |
30208477 |
dc.identifier.eid |
2-s2.0-85053660594 |